siTRP (short-term intervention To Revert Premalignancy) as strategy to prevent GI malignancy

다국어 초록 (Multilingual Abstract)

“Prevention might be better than treatment in cancer treatment” is brief conclusion drawn from war on cancer through National Cancer Act of 1971 by U.S. President Richard Nixon. However, the clinical practice of chemoprevention is still in its infancy in spite of a wealth of data showing its effectiveness in experimental animals as well as in vitro mechanism research. Recent advances in either high throughput analysis including cancer genomes and tailored medicine or molecular targeted therapeutics, preventive strategies also should be changes as previous preventive strategies including phytoceuticals, life-style modification, and some empirical agents. Furthermore, molecular targeted therapeutics achieved high goal of effectiveness under the concept of therapeutic or preventive “synthetic lethality”, of which extended application can be included within the scope of chemoprevention. Here, we will summarize several recent advances in chemopreventive strategy objected to justify optimism that chemoprevention will be an effective approach for the control of human cancer. siTRP (short-term intervention to revert premalignancy) strategy will be introduced for cancers in gastroenterology.

참고문헌 (Reference)

1 Bai H, "The effect of sulindac, a non-steroidal anti-inflammatory drug, attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis" 12 : 115-, 2012

2 Lee YC, "The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention" 62 : 676-682, 2013

3 Shaheen M, "Synthetic lethality: exploiting the addiction of cancer to DNA repair" 117 : 6074-6082, 2011

4 Soncini D, "Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer" 12 : 329-338, 2012

5 Porcelli L, "Synthetic lethality to overcome cancer drug resistance" 19 : 3858-3873, 2012

6 Garcea G, "Role of inflammation in pancreatic carcinogenesis and the implications for future therapy" 5 : 514-529, 2005

7 Nozaki K, "Reversibility of heterotopic proliferative glands in glandular stomach of Helicobacter pylori-infected Mongolian gerbils on eradication" 93 : 374-381, 2002

8 Hong WK, "Recent advances in chemoprevention of cancer" 278 : 1073-1077, 1997

9 Ock CY, "Prevention of colitisassociated colorectal cancer with 8-hydroxydeoxyguanosine" 4 : 1507-1521, 2011

10 Kim YJ, "Prevention of colitis-associated carcinogenesis with infliximab" 3 : 1314-1333, 2010

11 de Moura CF, "Polyphenols as a chemopreventive agent in oral carcinogenesis: putative mechanisms of action using in-vitro and in-vivo test systems" 22 : 467-472, 2013

12 Kim YJ, "Oxidative stress in inflammation- based gastrointestinal tract diseases: challenges and opportunities" 27 : 1004-1010, 2012

13 Foy JP, "Oral premalignancy: the roles of early detection and chemoprevention" 46 : 579-597, 2013

14 Yoo BM, "Novel antioxidant ameliorates the fibrosis and inflammation of cerulein-induced chronic pancreatitis in a mouse model" 5 : 165-176, 2005

15 Rajamanickam S, "Natural products and colon cancer: current status and future prospects" 69 : 460-471, 2008

16 Milind R, "Natural history of Barrett’s esophagus" 18 : 3483-3491, 2012

17 Huang S, "Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo" 4 : 666-673, 2011

18 Bai H, "Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/ Pdx1-Cre mice" 32 : 1689-1696, 2011

19 Farrow B, "Inflammation and the development of pancreatic cancer" 10 : 153-169, 2002

20 Miyashita T, "Impact of inflammation-metaplasia-adenocarcinoma sequence and prevention in surgical rat models" 87 : 6-11, 2013

21 Liu RH., "Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals" 78 : 517-520, 2003

22 Cao X, "Eradication of Helicobacter pylori induces apoptosis and inhibits proliferation of heterotopic proliferative glands in infected Mongolian gerbils" 95 : 872-877, 2004

23 Tatematsu M, "Effects of eradication of Helicobacter pylori on gastric carcinogenesis in experimental models" 42 : 7-9, 2007

24 Greenwald P, "Do we make optimal use of the potential of cancer prevention?" 181 : 3-17, 2009

25 Albazaz R, "Cyclooxygenase- 2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer" 5 : 361-369, 2005

26 Actis GC, "Cutting edge: chemoprevention of colorectal neoplasia in inflammatory bowel disease. Inflamm Allergy Drug Targets 2013;12:1-7" 12 : 1-7, 2013

27 Gill S, "Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?" 32 : 24-34, 2005

28 Half E, "Colon cancer: preventive agents and the present status of chemoprevention" 10 : 211-219, 2009

29 Cooper K, "Chemoprevention of colorectal cancer: systematic review and economic evaluation" 14 : 1-206, 2010

30 Subramanian V, "Chemoprevention of colorectal cancer in inflammatory bowel disease" 25 : 593-606, 2011

31 천경수, "Chemoprevention of Gastrointestinal Cancer: The Reality and the Dream" 거트앤리버 발행위원회 7 (7): 137-149, 2013

32 Gordon V, "Chemoprevention in Barrett’s oesophagus" 25 : 569-579, 2011

33 Terhaar Sive Droste JS, "Chemoprevention for colon cancer: new opportunities, fact or fiction?" 158-164, 2006

34 Papadimitrakopoulou VA., "Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal" 12 : 240-245, 2000

35 Lippman SM, "Cancer prevention: from 1727 to milestones of the past 100 years" 69 : 5269-5284, 2009

36 Papadimitrakopoulou VA, "Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer" 88 : 852-855, 2000

37 Cao X, "Beta-catenin gene alteration in glandular stomach adenocarcinomas in N-methyl-N-nitrosourea-treated and Helicobacter pylori-infected Mongolian gerbils" 95 : 487-490, 2004

38 Spechler SJ, "Barrett’s esophagus: Clinical issues" 21 : 1-7, 2011

39 Dent J, "Barrett’s esophagus: A historical perspective, an update on core practicalities and predictions on future evolutions of management" 26 (26): 11-30, 2011

40 Phillips WA, "Barrett’s esophagus" 26 : 639-648, 2011

41 Badreddine RJ, "Barrett esophagus: an update" 7 : 369-378, 2010

42 Meyskens FL Jr, "Back to the future: mechanism- based, mutation-specific combination chemoprevention with a synthetic lethality approach" 4 : 628-632, 2011

43 Wu X, "An intermittent approach for cancer chemoprevention" 11 : 879-885, 2011

44 Greenwald P, "A favorable view: progress in cancer prevention and screening" 174 : 3-17, 2007